Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver‐selective thyroid hormone receptor agonist eprotirome
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Liver‐selective thyromimetic agents could provide a new approach for treating dyslipidaemia. Methods: We performed a multicentre, randomized, placebo‐controlled, double‐blind study to evaluate the efficacy and safety of eprotirome, a liver‐selective thyroid hormone receptor agonist, in 98 patients with primary hypercholesterolaemia. After previous drug wash‐out and dietary run‐in, patients received 100 or 200 μg day−1 eprotirome or placebo for 12 weeks. The primary end‐point was change in serum LDL cholesterol; secondary end‐points included changes in other lipid parameters and safety measures. Results: Eprotirome treatment at 100 and 200 μg daily reduced serum LDL cholesterol levels by 23 ± 5% and 31 ± 4%, respectively, compared with 2 ± 6% for placebo (P < 0.0001). Similar reductions were seen in non‐HDL cholesterol and apolipoprotein (apo) B, whereas serum levels of HDL cholesterol and apo A‐I were unchanged. There were also considerable reductions in serum triglycerides and lipoprotein(a), in particular in patients with elevated levels at baseline. There was no evidence of adverse effects on heart or bone and no changes in serum thyrotropin or triiodothyronine, although the thyroxine level decreased. Low‐grade increases in liver enzymes were evident in most patients. Conclusion: In hypercholesterolaemic patients, the liver‐selective thyromimetic eprotirome decreased serum levels of atherogenic lipoproteins without signs of extra‐hepatic side effects. Selective stimulation of hepatic thyroid hormone receptors may be an attractive way to modulate lipid metabolism in hyperlipidaemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
Sex hormone-binding globulin and risk of type 2 diabetes in women and men
Ding, E. L., Song, Y., Manson, J. E., Hunter, D. J., Lee, C. C., Rifai, N., Buring, J. E., Gaziano, J. M., & Liu, S. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804381 · Cited by 726
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60545-4 · Cited by 716
Brunzell, J. D. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp070061 · Cited by 268
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227
Thyroid hormone crosstalk with nuclear receptor signaling in metabolic regulation
Liu, Y.-Y., & Brent, G. A. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.11.004 · Cited by 218
Stanworth, R. D., Kapoor, D., Channer, K. S., & Jones, T. H. (2009) · Diabetes Care · doi:10.2337/dc08-1183 · Cited by 88
Cited by
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
“Eprotirome therapy was associated with decreases in serum LDL, apolipoprotein B, triglycerides, and Lp(a) lipoprotein when added to statin therapy (668) and given as single therapy in primary hypercholesterolemia (670).”
Klein, I., & Danzi, S. (2016) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2015.04.002 · Cited by 218
Self-citationThyroid hormone signaling and the liver
Ritter, M. J., Amano, I., Hollenberg, A. N., et al. (2020) · Hepatology · doi:10.1002/hep.31296 · Cited by 188
“serum TAG reduction on 200-mg dose, but not 100-mg dose Transient increase in ALT (113)”
BackgroundInfluentialNAFLD and thyroid function: pathophysiological and therapeutic considerations
Hatziagelaki, E., Paschou, S. A., Schön, M., Psaltopoulou, T., & Roden, M. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2022.08.001 · Cited by 93
“While one study showed that KB2115 can decrease circulating atherogenic lipoproteins without signs of extra-hepatic side effects [104], the AKKA Phase 3 clinical trial demonstrated that KB2115 may lower LDL cholesterol, but can also induce hepatic injury”
BackgroundJonas, W., Lietzow, J., Wohlgemuth, F., Hoefig, C. S., Wiedmer, P., Schweizer, U., Köhrle, J., & Schürmann, A. (2015) · Endocrinology · doi:10.1210/en.2014-1604 · Cited by 90
Metadata
- Authors
- Angelin, B., Kristensen, J. D., Eriksson, M., Carlsson, B., Klein, I., Olsson, A. G., Chester Ridgway, E., & Ladenson, P. W.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2014-05-16
- Volume
- 277
- Issue
- 3
- Pages
- 331-342
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2144581648
- Cited by
- 55
- References
- 8
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver‐selective thyroid hormone receptor agonist eprotirome. https://app.cochat.ai/papers/10.1111/joim.12261
- The paper
- Angelin, B., Kristensen, J. D., Eriksson, M., Carlsson, B., Klein, I., Olsson, A. G., Chester Ridgway, E., & Ladenson, P. W. (2015). Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver‐selective thyroid hormone receptor agonist eprotirome. Journal of Internal Medicine. https://doi.org/10.1111/joim.12261
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.